Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models

Paul R. Gavine, Q. May Wang|Molecular Oncology|2014

Cited by 120